Kintegral Advisory LLC Sells 11,174 Shares of Illumina, Inc. (NASDAQ:ILMN)

Kintegral Advisory LLC cut its holdings in shares of Illumina, Inc. (NASDAQ:ILMN - Free Report) by 32.9% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 22,783 shares of the life sciences company's stock after selling 11,174 shares during the period. Kintegral Advisory LLC's holdings in Illumina were worth $1,808,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently made changes to their positions in ILMN. Capital World Investors increased its position in Illumina by 408.6% during the 4th quarter. Capital World Investors now owns 18,025,301 shares of the life sciences company's stock valued at $2,408,721,000 after buying an additional 14,481,232 shares in the last quarter. WCM Investment Management LLC grew its stake in shares of Illumina by 1.2% during the first quarter. WCM Investment Management LLC now owns 4,179,011 shares of the life sciences company's stock worth $334,321,000 after acquiring an additional 49,156 shares during the last quarter. Brown Advisory Inc. increased its holdings in shares of Illumina by 54,220.9% during the fourth quarter. Brown Advisory Inc. now owns 1,912,639 shares of the life sciences company's stock valued at $255,586,000 after acquiring an additional 1,909,118 shares in the last quarter. Norges Bank purchased a new position in shares of Illumina in the 4th quarter valued at approximately $228,714,000. Finally, Northern Trust Corp boosted its stake in Illumina by 26.9% in the 4th quarter. Northern Trust Corp now owns 1,652,935 shares of the life sciences company's stock worth $220,882,000 after purchasing an additional 349,878 shares in the last quarter. Hedge funds and other institutional investors own 89.42% of the company's stock.

Illumina Stock Performance

Shares of ILMN traded up $0.10 during trading hours on Friday, reaching $100.44. 1,423,748 shares of the company's stock traded hands, compared to its average volume of 2,144,110. The firm has a market capitalization of $15.90 billion, a price-to-earnings ratio of -16.55, a P/E/G ratio of 1.98 and a beta of 1.36. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.86 and a quick ratio of 1.48. Illumina, Inc. has a twelve month low of $68.70 and a twelve month high of $156.66. The business's fifty day simple moving average is $84.58 and its two-hundred day simple moving average is $98.02.

Illumina (NASDAQ:ILMN - Get Free Report) last released its quarterly earnings data on Thursday, May 8th. The life sciences company reported $0.97 EPS for the quarter, topping analysts' consensus estimates of $0.96 by $0.01. Illumina had a positive return on equity of 25.54% and a negative net margin of 22.25%. The firm had revenue of $1.04 billion for the quarter, compared to the consensus estimate of $1.03 billion. During the same quarter in the prior year, the company posted $0.98 earnings per share. The firm's revenue was down 1.4% on a year-over-year basis. Analysts predict that Illumina, Inc. will post 4.51 earnings per share for the current year.

Insider Buying and Selling

In other Illumina news, CFO Ankur Dhingra purchased 6,100 shares of the company's stock in a transaction on Monday, May 12th. The shares were bought at an average cost of $81.21 per share, with a total value of $495,381.00. Following the transaction, the chief financial officer directly owned 24,906 shares in the company, valued at approximately $2,022,616.26. This represents a 32.44% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is accessible through the SEC website. 2.60% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on the stock. Canaccord Genuity Group upped their price target on shares of Illumina from $87.00 to $99.00 and gave the company a "hold" rating in a research note on Wednesday, June 11th. Morgan Stanley cut their target price on Illumina from $136.00 to $100.00 and set an "equal weight" rating on the stock in a research report on Monday, May 12th. Piper Sandler lowered their price target on Illumina from $190.00 to $185.00 and set an "overweight" rating for the company in a research report on Thursday, May 15th. Citigroup dropped their price target on Illumina from $90.00 to $85.00 and set a "neutral" rating on the stock in a research note on Monday, April 7th. Finally, Royal Bank Of Canada reduced their price objective on Illumina from $128.00 to $112.00 and set an "outperform" rating for the company in a research note on Tuesday, April 8th. One investment analyst has rated the stock with a sell rating, nine have issued a hold rating, nine have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, Illumina currently has an average rating of "Moderate Buy" and an average price target of $127.39.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.